Coherus Oncology
CHRS
112 hedge funds and large institutions have $40.4M invested in Coherus Oncology in 2025 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 33 increasing their positions, 33 reducing their positions, and 20 closing their positions.
220% more call options, than puts
Call options by funds: $128K | Put options by funds: $40K
0% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 33
4% less funds holding
Funds holding: 117 → 112 (-5)
5.77% less ownership
Funds ownership: 53.47% → 47.7% (-5.8%)
19% less capital invested
Capital invested by funds: $50M → $40.4M (-$9.58M)
25% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$686K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$289K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$177K |
| 4 |
LPL Financial
San Diego,
California
|
+$117K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$116K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$3.79M |
| 2 |
Millennium Management
New York
|
-$1.31M |
| 3 |
Los Angeles Capital Management
Los Angeles,
California
|
-$521K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$502K |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$482K |
CHRS Hedge Fund Activity: Q2 2025 in Review
112 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q2 2025, worth a combined $40.4M — down 19% from $50M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of CHRS and 15 opened new positions — a net loss of 5 holders — while 33 trimmed existing stakes and 33 added.
The largest buyer was Panagora Asset Management, opening a new position worth an estimated $686K. The largest seller was Rubric Capital Management (New York), cutting an estimated $3.79M.
- 112 institutional investors held Coherus Oncology (CHRS) as of Q2 2025, down from 117 in Q1 2025.
- Funds reported $40.4M of Coherus Oncology stock for Q2 2025, down 19% quarter-over-quarter.
- 15 funds opened new Coherus Oncology positions in Q2 2025 and 20 closed out, a net change of -5 holders.
- The largest Coherus Oncology buyer in Q2 2025 was Panagora Asset Management, an estimated $686K added.
- The largest Coherus Oncology seller in Q2 2025 was Rubric Capital Management (New York), an estimated $3.79M sold.
Based on aggregated 13F filings for Q2 2025.